Detection of NRAS G12D and NRAS G13C mutant genes among apparently healthy and haematologic malignant individuals in Federal Capital Territory, Nigeria

References

• Liang, D. C.; Chen, S. H.; Liu, H. C.; Yang, C. P.; Yeh, T. C.; Jaing, T. H.; Hung, I. J.; Hou, J. Y.; Lin, T. H.; Lin, C. H.; et al. Mutational Status of NRAS, KRAS, and PTPN11 Genes Is Associated with Genetic/Cytogenetic Features in Children with B-precursor Acute Lymphoblastic Leukemia. Pediatr. Blood Cancer 2018, 65, e26786. DOI: 10.1002/pbc.26786.
   Web of Science ®Google Scholar
• McCubrey, J. A.; Steelman, L. S.; Abrams, S. L.; Lee, J. T.; Chang, F.; Bertrand, F. E.; Navolanic, P. M.; Terrian, D. M.; Franklin, R. A.; D’Assoro, A. B.; et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT Pathways in Malignant Transformation and Drug Resistance. Adv. Enzyme Regul. 2006, 46, 249–279. DOI: 10.1016/j.advenzreg.2006.01.004.
   PubMedGoogle Scholar
• World Health Organisation. Cancer: Key Statistics. 2019. https://www.who.int/cancer/resources/keyfacts/en/
   Google Scholar
• Onwuasigwe, C. N.; Aniebue, P. N.; Ndu, A. C. Spectrum of Paediatric Malignancies in Eastern Nigeria (1989–1998). West Afr. J. Med. 2002, 21(1), 31–33.
   PubMedGoogle Scholar
• Omoti, C. E.; Halim, N. K. Plasma Cell Myeloma in a Tertiary Centre in the Niger Delta Region of Nigeria: Clinicoimmunologic Analysis. Pak. J. Med. Sci. 2006, 23(1), 27–32.
   Web of Science ®Google Scholar
• Omoti, C. E.; Imiere, E. O. Trends in the Pattern of Leukaemia Incidence in a Tertiary Health Care Centre in Nigeria: 1990–2004. J. Med. Biomed. Res. 2006, 5(2), 44–49.
   Google Scholar
• Nwannadi, I. A.; Alao, O. O.; Bazuaye, G. N.; Halim, N. K. The Epidemiology of Haematological Malignancies at the University of Benin Teaching Hospital: A Ten-year Retrospective Study. Int. J. Epidemiol. 2010, 9. DOI: 10.5580/1fbb.
   Google Scholar
• Omoti, C. E.; Nwannadi, I. A.; Obieche, J. C.; Olu-Eddo, A. N. The Epidemiological Features of Lymphoid Malignancies in Benin City, Nigeria: A15 Years Study. Pan. Afr. Med. J. 2012, 11, 10.
   PubMedGoogle Scholar
• Egesie, O. J.; Agaba, P. A.; Silas, O. A.; Achenbach, C.; Zoakah, A.; Agbaji, O.; Madaki, J. A.; Okeke, E. N.; Hou, L.; Sagay, A. S.; et al. Presentation and Survival in Patients with Hematologic Malignancies in Jos, Nigeria: A Retrospective Cohort Analysis. J. Med. Trop. 2018, 20, 49–56. DOI: 10.4103/jomt.jomt_8_18.
   PubMedGoogle Scholar
• Fernández-Medarde, A.; Santos, E. Ras in Cancer and Developmental Diseases. Genes Cancer 2011, 2(3), 344–358. DOI: 10.1177/1947601911411084.
   PubMedGoogle Scholar
• Vasioukhin, V.; Anker, P.; Maurice, P.; Lyautey, J.; Lederrey, C.; Stroun, M. Point Mutations of the N-ras Gene in the Blood Plasma DNA of Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukaemia. Br. J. Haematol. 1994, 86, 774–779. DOI: 10.1111/j.1365-2141.1994.tb04828.x.
   PubMed Web of Science ®Google Scholar
• Williams, C. K.;. Neoplastic Diseases of the Haemopoietic System in Ibadan: Preliminary Report of a Prospective Study. Afr. J. Med. Sci. 1985, 14, 89–94.
   Google Scholar
• Kagu, M. B.; Ahmed, S. G.; Bukar, A. A.; Mohammed, A. A.; Mayun, A. A.; Musa, A. B. Spectrum of Haematologic Malignancies and Survival Outcomes of Adult Lymphomas in Maiduguri, Northeastern Nigeria − A Fourteen-year Review. Afr. J. Med. Med. Sci. 2013, 42, 5–14.
   PubMedGoogle Scholar
• Liang, D. C.; Shih, L. Y.; Fu, J. F.; Li, H. Y.; Wang, H. I.; Hung, I. J.; Yang, C. P.; Jaing, T. H.; Chen, S. H.; HC, L. K-Ras Mutations and NRAS Mutations in Childhood Acute Leukemias with or without Mixed-lineage Leukemia Gene Rearrangements. Cancer 2006, 106, 950–956. DOI: 10.1002/cncr.21730.
   PubMed Web of Science ®Google Scholar
• Bacher, U.; Haferlach, T.; Schoch, C.; Kern, W.; Schnittger, S. Implications of NRAS Mutations in AML: A Study of 2502 Patients. Blood 2006, 107(10), 3847–3853. DOI: 10.1182/blood-2005-08-3522.
   PubMed Web of Science ®Google Scholar
• Xia, L.; Li, Z.; Zhou, B.; Tian, G.; Zeng, L.; Dai, H.; Li, X.; Liu, C.; Lu, S.; Xu, F.; et al. Statistical Analysis of Mutant Allele Frequency Level of Circulating Cell-free DNA and Blood Cells in Healthy Individuals. Sci. Rep. 2017, 7, 7526. DOI: 10.1038/s41598-017-06106-1.
   PubMed Web of Science ®Google Scholar
• Risques, R. A.; Kennedy, S. R. Aging and the Rise of Somatic Cancer-associated Mutations in Normal Tissues. PLoS Genet. 2018, 14(1), e1007108. DOI: 10.1371/journal.pgen.1007108.
   PubMed Web of Science ®Google Scholar
• Bowen, D. T.; Frew, M. E.; Hills, R.; Gale, R. E.; Wheatley, K. RAS Mutation in Acute Myeloid Leukemia Is Associated with Distinct Cytogenetic Subgroups but Does Not Influence Outcome in Patients Younger than 60 Years. Blood 2005, 106, 2113–2119. DOI: 10.1182/blood-2005-03-0867.
   PubMed Web of Science ®Google Scholar
• Wang, J.; Liu, Y.; Li, Z.; Wang, Z.; Tan, L. X.; Ryu, M.-J.; Meline, B.; Du, J.; Young, K. H.; Ranheim, E.; et al. Endogenous Oncogenic Nras Mutation Initiates Hematopietic Malignancies in a Dose- and Cell Type-dependent Manner. Blood 2011, 118(2), 368–379. DOI: 10.1182/blood-2010-12-326058.
   PubMed Web of Science ®Google Scholar
• Le, D. T.; Shannon, K. M. Ras Processing as a Therapeutic Target in Hematologic Malignancies. Curr. Opin. Hematol. 2002, 9(4), 308–315.
   PubMed Web of Science ®Google Scholar
• Janku, F.; Wheler, J. J.; Hong, D. S.; Kurzrock, R. Bevacizumab-based Treatment in Colorectal Cancer with a NRAS Q61K Mutation. Target Oncol. 2013, 8(3), 183–188. DOI: 10.1007/s11523-013-0266-9.
   PubMed Web of Science ®Google Scholar
• Marin, G.; Bruzzoni-Giovanelli, H.; Schinella, G. T Cell Leukemia Control via Ras-Raf Pathway Inhibition with Peptides. J. Med. Life 2017, 10(3), 172–175.
   PubMedGoogle Scholar